NCT05710380

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Conditions

• Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Neoplasm

Interventions

Type	Name	Description
OTHER	Risk Map Decision Support System (DSS).	The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
RADIATION	Magnetic Resonance Imaging (MRI)	A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
PROCEDURE	Magnetic Resonance Imaging (MRI) Guided Biopsy	A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.

Timeline

• Start date: 2023-04-26
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2023-02-02
• Last updated: 2025-10-01

Locations

1 site across 1 country: United States